TG Therapeutics is in a sustained uptrend, with the stock up 46.9% over the past year, significantly outperforming the S&P 500's 19.1% gain. The current price of $53.31 sits at 93% of its 52-week range ($25.28–$57.38), indicating the stock is near its highs and reflecting strong bullish momentum. This positioning near the top of the range suggests the market is pricing in continued positive catalysts, though it also raises the risk of overextension in the near term. Short-term momentum is exceptionally strong, with the stock surging 45.5% in the past month and 59.0% in the past three months, far outpacing the S&P 500's -1.25% and 13.56% returns, respectively. This accelerating momentum aligns with the longer-term uptrend, showing no signs of divergence, and the relative strength index (implied by the price action) suggests the stock is in a powerful breakout phase. The 52-week low of $25.28 provides a clear support level, while the 52-week high of $57.38 acts as immediate resistance. A breakout above $57.38 would signal a continuation of the uptrend and open the door to further gains, while a breakdown below $25.28 would be a major reversal signal. With a beta of 1.597, the stock is nearly 60% more volatile than the market, meaning larger swings in both directions, which is critical for risk management.

TG Therapeutics is experiencing rapid revenue growth, with Q4 2025 revenue of $192.6 million, up 78% year-over-year from $108.2 million in Q4 2024. This marks a significant acceleration from the 29% growth in Q3 2024 and 16% in Q2 2024, driven by the commercial launch of BRIUMVI. Product revenue of $189.1 million in Q4 2025 dominates the top line, supplemented by $5.0 million in royalty income and $3.0 million in other revenue, indicating a highly concentrated revenue stream. The company has achieved profitability, reporting net income of $23.0 million in Q4 2025, compared to a net loss of $10.7 million in Q1 2024, demonstrating a rapid turnaround. Gross margin is strong at 80.2% in Q4 2025, though slightly down from 85.8% in Q2 2025, likely due to product mix or manufacturing scale-up. Operating margin improved to 26.2% in Q4 2025 from 7.1% in Q1 2025, reflecting operating leverage as revenue scales. The balance sheet is healthy with a current ratio of 4.1 and a debt-to-equity ratio of 0.40, indicating low financial risk. Free cash flow turned positive at $19.6 million in Q4 2025, compared to negative free cash flow in prior quarters, showing the business is now self-funding. ROE is an impressive 69.0%, though this is elevated due to a relatively small equity base, and the company has $80.5 million in cash at the end of 2025.